In new deal, As­traZeneca places small bet on 'crit­i­cal but chal­leng­ing' tar­get

Last week
Deals

Spec­trum im­plodes af­ter a harsh pub­lic slap­down and now a CRL from Richard Paz­dur

Last week
FDA+

Big Phar­ma's Twit­ter ex­o­dus; Mer­ck wa­gers $1.35B on buy­out; $3.5M gene ther­a­py; and more

Last week
Weekly

Roivant’s Der­ma­vant de­buts first-ever TV com­mer­cial for pso­ri­a­sis cream Vta­ma

3 weeks ago
Pharma
Marketing

Phar­ma re­new­able en­er­gy co-op sparks broad­er sup­pli­er push, fol­lows Wal­mart's lead

3 weeks ago
Pharma
Marketing

Gam­ing for phar­ma: Re­al Chem­istry adds video game mar­ket­ing to agency ex­per­tise

3 weeks ago
Pharma
Marketing

One hur­dle down? FDA won't hold ad­comm for Bio­Mar­in's he­mo­phil­ia gene ther­a­py af­ter all

3 weeks ago
Cell/Gene Tx

No­var­tis to ad­vance malar­ia pro­gram in­to PhI­II in bid to fight drug re­sis­tance

3 weeks ago
R&D

CSL lands FDA ap­proval for he­mo­phil­ia B gene ther­a­py, sets $3.5M list price

3 weeks ago
Cell/Gene Tx
FDA+

Phar­ma rep­u­ta­tion falls again, notch­ing dou­ble-dig­it down­turn over past year in US — sur­vey

3 weeks ago
Pharma
Marketing

Mar­ket­ingRx roundup: Am­gen and Sto­ryCorps launch health eq­ui­ty se­ries; Ab­b­Vie's $40M math and sci­ence school opens

3 weeks ago
Pharma
Marketing

Sur­prise da­ta drop by con­fer­ence puts Arv­inas in cleanup mode

3 weeks ago
R&D

Cy­cle­ri­on board quick­ly nix­es CEO Pe­ter Hecht's un­ortho­dox pitch for low cash re­serves

3 weeks ago
People
Deals

Sim­u­la­tions for ex­per­i­ments: Bay­er-backed start­up lands $20M to test out its tech

3 weeks ago
Financing
Startups

Days af­ter re­port­ing PhI­II fail­ure, GSK pulls BC­MA drug from US mar­ket — but it's not giv­ing up en­tire­ly yet

3 weeks ago
Pharma
FDA+

Take­da goes back to school, team­ing up with Dis­cov­ery Ed­u­ca­tion for health eq­ui­ty ini­tia­tive

3 weeks ago
Pharma
Marketing

Court KOs REMS-re­lat­ed patent list­ing for Jazz nar­colep­sy drug

3 weeks ago
Law

Mak­er of new gene ther­a­py vec­tor launch­es its sec­ond com­pa­ny, look­ing to ze­ro in on rare skin con­di­tions

3 weeks ago
Startups
Cell/Gene Tx

Six-per­son ALS biotech wants to go pub­lic — but it’s al­so piv­ot­ing from ear­li­er plans

3 weeks ago
Financing
R&D

Mer­ck KGaA spot­lights need for deals to shake up R&D, with ex­ter­nal part­ners key to new drugs

3 weeks ago
Pharma

Up­dat­ed: No Seagen here: 'Do more' means a small $1.35B pur­chase of Ima­go for Mer­ck

3 weeks ago
Deals
Pharma

Gene ther­a­py flunks PhII/III study, but for­mer Sarep­ta part­ner sees a path for­ward — if it can find the cash

3 weeks ago
R&D
Cell/Gene Tx

Alzheimer’s drug bites the dust; Re­struc­ture, re­struc­ture, re­struc­ture; Land­mark di­a­betes OK; and more

3 weeks ago
Weekly

Vi­iV takes to the couch for con­ver­sa­tions about HIV in its new ‘Sci­ence on the So­fa’ se­ries

3 weeks ago
Pharma
Marketing
First page Previous page 1234567 Next page Last page